Avinger's Shares Move Higher As Pantheris Shows Safety, Efficacy For In-Stent Restenosis

Avinger Inc AVGR has announced that clinical data from the INSIGHT study were presented at the VIVA (Vascular InterVentional Advances) conference.
The INSIGHT trial was designed to evaluate the safety and effectiveness of Avinger's Pantheris image-guided atherectomy system for in-stent restenosis (ISR) in lower extremity arteries.
Related: Avinger Files US Application For New Pantheris In-Stent Restenosis Indication.
Key outcomes presented from the trial include:
- 82% luminal gain (increase in the channel for blood flow) following the procedure.
- 93% freedom from target lesion restenosis at six months post-procedure.
- 89% freedom from target lesion restenosis at 12 months post-procedure.
- No amputations for the six or 12-month cohorts of patients.
- 0.96 mean ankle-brachial index at six months from a baseline of 0.69 pre-procedure. 71% improvement in Rutherford Class (a measure of disease severity) at six months.
Price Action: AVGR stock is up 14.1% at $0.79 during the market session on the last check Thursday.